Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline

Abstract

Non-alcoholic fatty liver disease (NAFLD) is the main cause of liver diseases in Spain and the incidence is raising due to the outbreak of type 2 diabetes and obesity. This CPG suggests recommendation about diagnosis, mainly non-invasive biomarkers, and clinical management of this entity. Life-style modifications to achieve weight loss is the main target in the management of NAFLD. Low caloric Mediterranean diet and 200 minutes/week of aerobic exercise are encouraged. In non-responders patients with morbid obesity, bariatric surgery or metabolic endoscopy could be indicated. Pharmacological therapy is indicated in patients with NASH and fibrosis and non-responders to weight loss measures. NAFLD could influence liver transplantation, as a growing indication, the impact of steatosis in the graft viability, de novo NAFLD rate after OLT and a raised cardiovascular risk that modify the management of this entity. The current CPG was the result of the First Spanish NAFLD meeting in Seville.

Keywords: Cardiovascular risk; Clinical guidelines; Diagnosis; Diagnóstico; Enfermedad por hígado graso no alcohólico; Esteatosis; Fibrosis; Guías clínicas; Non-alcoholic fatty liver disease; Recomendaciones; Recommendations; Riesgo cardiovascular; Steatosis; Tratamiento; Treatment.